Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$7,843 Mln
P/E Ratio
--
P/B Ratio
24.49
Industry P/E
--
Debt to Equity
0.01
ROE
-0.76 %
ROCE
-68.34 %
Div. Yield
0 %
Book Value
0.31
EPS
-0.27
CFO
$-305.72 Mln
EBITDA
$-402.86 Mln
Net Profit
$-360.30 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Verona Pharma - ADR
| 35.63 | -5.73 | 16.47 | 304.01 | 146.60 | 65.64 | -- |
|
BSE Sensex
| 1.99 | 3.77 | 4.29 | 8.22 | 11.74 | 20.16 | 11.15 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Verona Pharma - ADR
| 131.99 | -23.92 | 288.84 | -4.00 | 21.74 | -40.16 | -18.71 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.41 | 9,808.03 | 20.22 | 23.13 | |
| 299.04 | 8,956.09 | 22.08 | 58.42 | |
| 26.78 | 9,559.25 | -- | -28.77 | |
| 104.84 | 10,030.35 | 30.81 | 14.16 |
Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase... (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pulmonary disease, as well as cystic fibrosis and asthma. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom. Address: 3 More London Riverside, London, United Kingdom, SE1 2RE Read more
President, CEO & Executive Director
Dr. David S. Zaccardelli Pharm.D.
President, CEO & Executive Director
Dr. David S. Zaccardelli Pharm.D.
Headquarters
London
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Verona Pharma plc - ADR stood at $ 474 Mln as on 31-Dec-24
The share price of Verona Pharma plc - ADR is $62.99 (NASDAQ) as of 24-Apr-2025 11:44 EDT. Verona Pharma plc - ADR has given a return of 146.6% in the last 3 years.
Verona Pharma plc - ADR has a market capitalisation of $ 7,843 Mln as on 22-Apr-2025. As per Value Research classification, it is a company.
Since, TTM earnings of Verona Pharma plc - ADR is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Verona Pharma plc - ADR and enter the required number of quantities and click on buy to purchase the shares of Verona Pharma plc - ADR.
Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pulmonary disease, as well as cystic fibrosis and asthma. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom. Address: 3 More London Riverside, London, United Kingdom, SE1 2RE
The CEO & director of Dr. David S. Zaccardelli Pharm.D.. is Verona Pharma plc - ADR, and CFO & Sr. VP is Dr. David S. Zaccardelli Pharm.D..
There is no promoter pledging in Verona Pharma plc - ADR.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Verona Pharma plc - ADR | Ratios |
|---|---|
|
Return on equity(%)
|
-76.42
|
|
Operating margin(%)
|
-330.16
|
|
Net Margin(%)
|
-410.18
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Verona Pharma plc - ADR was $0 Mln.
$-0.33
(
